Jennifer K Straughen1, Pawan Kumar, Vinod K Misra. 1. Department of Family Medicine and Public Health Sciences, The Wayne State University School of Medicine, Detroit, MI, USA.
Abstract
OBJECTIVE: Soluble fms-like tyrosine kinase 1 (sFlt1) is an antiangiogenic protein that is associated with a number of disorders of placental angiogenesis. It has been hypothesized that disruption of placental angiogenesis may contribute to the pathophysiology of preterm delivery (PTD). However, the relationship of PTD risk to variation in sFlt1 levels is not well known. We investigate the relationship between longitudinal variation in maternal serum concentrations of sFlt1 and risk of PTD. METHODS: Data were collected in a longitudinal cohort study involving 278 pregnant women. Maternal serum sFlt1 concentrations were measured at 6-10, 10-14, 16-20, 22-26, and 32-36 weeks gestation. Data analyses used longitudinal regression models using repeated measures that allow robust inferences from our modest sample size. The outcome was birth prior to 37 weeks gestation. RESULTS: sFlt1 concentrations were higher in first trimester for preterm compared to term deliveries. This relationship reversed in second trimester because sFlt1 concentrations increased more rapidly across gestation for term deliveries. In Cox proportional hazards analyses, a 2 ng higher sFlt1 concentration across gestation was associated with a hazard ratio of 1.3 (95% CI: 1.1, 1.5) for PTD suggesting the importance of levels in early pregnancy. CONCLUSION: Elevated maternal serum sFlt1 concentration during pregnancy is associated with increased risk of PTD.
OBJECTIVE: Soluble fms-like tyrosine kinase 1 (sFlt1) is an antiangiogenic protein that is associated with a number of disorders of placental angiogenesis. It has been hypothesized that disruption of placental angiogenesis may contribute to the pathophysiology of preterm delivery (PTD). However, the relationship of PTD risk to variation in sFlt1 levels is not well known. We investigate the relationship between longitudinal variation in maternal serum concentrations of sFlt1 and risk of PTD. METHODS: Data were collected in a longitudinal cohort study involving 278 pregnant women. Maternal serum sFlt1 concentrations were measured at 6-10, 10-14, 16-20, 22-26, and 32-36 weeks gestation. Data analyses used longitudinal regression models using repeated measures that allow robust inferences from our modest sample size. The outcome was birth prior to 37 weeks gestation. RESULTS: sFlt1 concentrations were higher in first trimester for preterm compared to term deliveries. This relationship reversed in second trimester because sFlt1 concentrations increased more rapidly across gestation for term deliveries. In Cox proportional hazards analyses, a 2 ng higher sFlt1 concentration across gestation was associated with a hazard ratio of 1.3 (95% CI: 1.1, 1.5) for PTD suggesting the importance of levels in early pregnancy. CONCLUSION: Elevated maternal serum sFlt1 concentration during pregnancy is associated with increased risk of PTD.
Authors: Stefan Verlohren; Ignacio Herraiz; Olav Lapaire; Dietmar Schlembach; Manfred Moertl; Harald Zeisler; Pavel Calda; Wolfgang Holzgreve; Alberto Galindo; Theresa Engels; Barbara Denk; Holger Stepan Journal: Am J Obstet Gynecol Date: 2011-07-30 Impact factor: 8.661
Authors: Gordon C S Smith; Jennifer A Crossley; David A Aitken; Nicola Jenkins; Fiona Lyall; Alan D Cameron; J Michael Connor; Richard Dobbie Journal: Obstet Gynecol Date: 2007-06 Impact factor: 7.661
Authors: K D Kolstad; J A Mayo; L Chung; Y Chaichian; V M Kelly; M Druzin; D K Stevenson; G M Shaw; J F Simard Journal: BJOG Date: 2019-10-31 Impact factor: 6.531
Authors: Heather A Frey; Molly J Stout; Laurel N Pearson; Methodius G Tuuli; Alison G Cahill; Jerome F Strauss; Luis M Gomez; Samuel Parry; Jenifer E Allsworth; George A Macones Journal: Am J Obstet Gynecol Date: 2016-03-12 Impact factor: 8.661